Navigation Links
PhotoThera Closes $50 Million Financing, Announces New President and Chief Executive Officer
Date:4/30/2009

PREPARES FOR LAUNCH OF 'NEST-3' ACUTE ISCHEMIC STROKE CLINICAL TRIAL

CARLSBAD, Calif., April 30 /PRNewswire/ -- PhotoThera, Inc., the developer of transcranial laser therapy (TLT) designed for the treatment of acute ischemic stroke within 24 hours of stroke onset, announced today that it has closed a $50 million Series D round of financing led by Warburg Pincus, a leading global private equity firm, to fund a planned follow-on phase III 'NEST-3' (NeuroThera(R) Effectiveness and Safety Trial) clinical study. The Company previously announced that NEST-3 would build upon the results of its NEST-2 trial, which revealed a statistically significant treatment effect for patients with moderate to moderately severe ischemic strokes using a post-hoc data analysis.

In addition to Warburg Pincus, participating investors include The Vertical Group L.P., Hamilton BioVentures, Delphi Ventures, DeNovo Ventures, and certain individual members of Monterey Advisors, Inc.

PhotoThera also announced that Arthur T. Taylor, former Chief Operating Officer of Kyphon Inc., has been appointed as President and Chief Executive Officer. Taylor succeeds Thomas C. Wilder III who has decided to pursue other opportunities after successfully securing the Series D funding and serving as the Company's President and Chief Executive Officer since April 2006.

"I am very excited about the opportunity to lead PhotoThera during this critical period of building the clinical evidence to support use of our TLT technology in treating acute ischemic stroke patients," said Taylor.

Taylor most recently served as Vice President and General Manager for the Kyphon Products, Spinal & Biologics Business of Medtronic, Inc. Prior to Medtronic's acquisition of Kyphon in late 2007, Taylor served as Kyphon's Chief Operating Officer from 2006, and as Chief Financial Officer from 2004 through 2006. Prior to his Kyphon tenure, Taylor gained in-depth experience across the medical device industry while serving as Chief Financial Officer for ReSound Corporation, a hearing healthcare company, and in executive positions with Allergan, Inc. and American Hospital Supply Corporation. Taylor holds a B.S. in Corporate Finance from San Diego State University and an M.B.A. from the University of Southern California.

"With the strong foundation Tom Wilder helped to build and the addition to the team of Art's deep operating expertise, I believe we are well positioned to take full advantage of our promising NEST-2 results with the launch of NEST-3 to secure the necessary data to support commercialization of our TLT technology," said Jackson Streeter, M.D., Founder and Executive Chairman, PhotoThera.

The results of the NEST-2 study, which demonstrated both the safety of the TLT treatment and statistically significant effectiveness for certain cohorts of stroke patients, were recently presented at the American Heart Association's International Stroke Conference in San Diego, California, by Justin Zivin, M.D., Ph.D., Professor of Neurosciences at the University of California San Diego and Principal Investigator for the NEST-2 study. The results were also published online in Stroke: Journal of the American Heart Association on February 20, 2009.

About PhotoThera, Inc.

PhotoThera, Inc. (www.photothera.com), located in Carlsbad, California, is developing transcranial laser therapy (TLT) for the treatment of acute ischemic stroke and other neurological diseases and disorders. According to the American Stroke Association, stroke is the third leading cause of death in the United States with approximately 700,000 strokes annually. Ischemic stroke, which accounts for about 83 percent of all strokes, occurs as a result of an obstruction within a blood vessel supplying blood to the brain.

About Warburg Pincus

Warburg Pincus is a leading global private equity firm. The firm has approximately $30 billion of assets under management including $10 billion available for investment in a range of sectors including healthcare, financial services, energy, technology, media, telecommunications, consumer, industrial and real estate. Its active portfolio of more than 100 companies is highly diversified by stage, sector and geography. Warburg Pincus is a growth investor and an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 12 private equity funds which have invested more than $29 billion in approximately 600 companies in 30 countries. The firm has offices in Beijing, Frankfurt, Hong Kong, London, Mumbai, New York, San Francisco, Shanghai and Tokyo. For more information, please visit www.warburgpincus.com.


'/>"/>
SOURCE PhotoThera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ProAssurance Closes PICA Transaction
2. Conseco Closes Amendment to Credit Facility
3. ReGear Life Sciences Closes $2.5 Million in Series A Financing Following $1M Investment by Stonewood Capital Management, Inc.
4. GetWellNetwork Closes $10 Million Financing, Eight Hospitals Choose PatientLife System(R) for Unparalleled Patient Care
5. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
6. Hard To Treat Diseases (HTDS) Closes Acquisition of Mellow Hope, China
7. MassMutual Breast Cancer Awareness Campaign Closes with Six-Figure Donation, Greater Understanding of Importance of Financial Preparedness
8. Noteworthy Medical Systems, Inc. Secures Capital from Top European eHealth Provider and Closes on Merger with Strategic Partner
9. Patient Safety Technologies Closes $2.55 Million Financing
10. Summer Street Research Partners Closes Two More Healthcare Company Financings
11. Acclarent, Inc. Closes $26 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs ... properties including its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) ... Nothing Water has been available in several ShopRite and FoodTown stores in NJ and ...
(Date:12/2/2016)... Abilene, Texas (PRWEB) , ... December 02, 2016 , ... ... article that delves into how this current generation fits into Bible Prophecy. Yisrayl says ... lists various facts pointing to this conclusion, showing how the details line up exactly ...
(Date:12/2/2016)... Francisco, CA (PRWEB) , ... December 02, 2016 ... ... digitally-enabled care journeys, announced today that it has raised $6.0 million in an ... inspired by Clarify Health’s conviction that patients and their caregivers can receive far ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a secure, ... was named the best Sales Team of 2016 as part of the 2016 ... by the Software & Information Industry Association (SIIA), the principal trade association for ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for ... $1,000 each from the National Family Partnership and the Drug Enforcement Administration as part ... their homes and the 10 winning schools who decorated their campuses with this year’s ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  The Addiction Treatment Advisory ... of Managed Care Pharmacy (AMCP), has released detailed ... address the opioid addiction crisis, including through improved ... ATAG,s newly released paper, "The Role ... Naloxone," addresses many issues around gaps and barriers ...
(Date:12/2/2016)... 2016 CVS Health Corporation (NYSE: ... York City on Thursday, December 15, 2016, beginning at 8:00 a.m. (ET). ... provide an in-depth review of the company,s strategies to ... will also discuss 2017 earnings guidance during the event. ... event will be broadcast simultaneously on the Investor Relations ...
(Date:12/2/2016)... 2, 2016   CytoSorbents Corporation (NASDAQ: ... European Union approved CytoSorb ® cytokine adsorber to ... worldwide, announced that Dr. Phillip Chan , Chief ... LD Micro Main Event investor conference held from ... Luxe Sunset Boulevard Hotel in Los Angeles, ...
Breaking Medicine Technology: